BioAxone BioSciences
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
90 Canal St Ste 4, Boston, Massachusetts...Phone Number
(617) 401-3115Website
www.bioaxonebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BioAxone BioSciences
BioAxone BioSciences Inc. is a biopharmaceutical company focused on developing innovative drugs aimed at restoring neurological function for patients with spinal cord injuries and neurovascular disorders. The company is in the clinical stage, working on drug candidates that promote axon regeneration and neuronal signaling pathways. Their treatments target conditions such as spinal cord injury, which leads to paralysis, and cerebral cavernous malformation, a blood vessel disorder that can cause severe neurological damage. BioAxone aims to transform the lives of patients by providing effective therapies where none currently exist.Explore more
BioAxone BioSciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioAxone BioSciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioAxone BioSciences had a recent Job posting/layoffs
Earning: See what the market has to say on BioAxone BioSciences recently announced quarterly report
Funding: Get notified immidiatlly once BioAxone BioSciences has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioAxone BioSciences
Check if BioAxone BioSciences has recently received funding, and reach out quickly before it becomes old news!
BioAxone BioSciences, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BioAxone BioSciences launches new products
Check out if BioAxone BioSciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined BioAxone BioSciences as Masked Content
Find more new buyers
Compare Similar Companies to BioAxone BioSciences
Compare insights from companies similar to BioAxone BioSciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioAxone BioSciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioAxone BioSciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioAxone BioSciences.
BioAxone BioSciences Tech Stack
A closer look at the technologies used by BioAxone BioSciences
BioAxone BioSciences News & Media
BioAxone BioSciences Announces License of Cerebral Cavernous Malformations Drug Candidate BA-1049 and Portfolio of Rho Kinase Inhibitors to Neurelis
BOSTON--(BUSINESS WIRE)--BioAxone BioSciences today announced the license of BA-1049, its innovative orally-available ROCK2 inhibitor targeting CCMs, to Neurelis, Inc.Neurelis Announces Acquisition Of Rights To Portfolio Of New Chemical Entity (NCE) Compounds Targeting Cerebral Cavernous Malformations, A Rare CNS Disorder
SAN DIEGO, June 21, 2021 /PRNewswire/ -- Neurelis, Inc., announced today that it has acquired from BioAxone Biosciences, Inc. a portfolio of novel ROCK-2 Inhibitors that target cerebral cavernous malformations (CCMs), a rare disorder of the central nervous system (CNS) that currently have...Neurelis Announces Acquisition Of Rights To Portfolio Of New Chemical Entity (NCE) Compounds ...
/PRNewswire/ -- Neurelis, Inc., announced today that it has acquired from BioAxone Biosciences, Inc. a portfolio of novel ROCK-2 Inhibitors that target...BioAxone BioSciences Announces Notice of Allowance for Self-Delivering RNA Interference for the Treatment of Spinal Cord Injury
BOSTON--(BUSINESS WIRE)--BioAxone BioSciences, Inc., a biotechnology company applying an innovative understanding of axon regeneration and neuronal signaling to transform the lives of patients afflicted with neurotrauma or neurovascular disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The notice covers the critical patent application (US 16/321,229) for the proprietary method of treatment of spinal cord injury with
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioAxone BioSciences
Sign Up For FreeTo access detailed company insights
BioAxone BioSciences Inc. is a biopharmaceutical company focused on developing innovative drugs aimed at restoring neurological function for patients with spinal cord injuries and neurovascular disorders. The company is in the clinical stage, working on drug candidates that promote axon regeneration and neuronal signaling pathways. Their treatments... Read More
